Include discussions and review of systems regarding inflammatory bowel disease in patients starting isotretinoin therapy

Archives of Dermatology

Volumn 147, Issue 6, 2011, Pages 729-730

  Mostow, Eliot N ^a  

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ACNE; DERMATOLOGY; DISEASE SEVERITY; ENTERITIS; FAMILY HISTORY; HUMAN; NOTE; PATIENT CARE; PATIENT EDUCATION; PRIORITY JOURNAL; RESPONSIBILITY; SYMPTOMATOLOGY; ULCERATIVE COLITIS;

ACNE VULGARIS; DERMATOLOGIC AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; ISOTRETINOIN; LIABILITY, LEGAL;

EID: 79959437150     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.131     Document Type: Note

References (4)

1. Popescu CM, Popescu R. Isotretinoin therapy and inflammatory bowel disease. Arch Dermatol. 2011;147(6):724-729.
2. Gupta AK, Lynde CW, Poulin Y, Smith K, Lewis R, Zip C; Pharmacy and Therapeutics Committee, Canadian Dermatology Association. Position statement for isotretinoin. J Cutan Med Surg. 2007;11(3):123-124.
3. American Academy of Dermatology. Position statement on isotretinoin (latest update November 13, 2010) . http://www.aad.org/Forms/Policies/Uploads/ PS/PS-Isotretinoin.pdf. Accessed April 20, 2011.
4. Strauss JS, Krowchuk DP, Leyden JJ, et al; American Academy of Dermatology/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management. J Am Acad Dermatol. 2007;56(4):651-663.